Molecular medicine in lung cancer

Improving care for cancer patients

Managing cancer and living meaningfully

Dacomitinib for EGFR positive lung cancer

New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Immunotherapy may slow the growth of malignant pleural mesothelioma

Immunotherapy for mesothelioma could be on the horizon

Alectinib eclipses crizotinib for ALK positive lung cancer

New personalised therapies for lung cancer

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Nivolumab for NSCLC: five years on